Login
Navigate Fool.com
Will MNKD beat
the market?

MannKind Corp (NASDAQ: MNKD)

Community Rating: 2 Stars: Unattractive

9.00 -0.56 (-5.86%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $9.50
Previous Close $9.56
Daily Range $8.71 - $9.57
52-Week Range $3.80 - $11.48
Market Cap $3.5B
P/E Ratio -15.17
Dividend (Yield) $0.00 (0.0%)
Volume 13,953,557
Average Daily Volume 10,631,942
Current FY EPS -$0.37

How do you think MNKD
will perform against the market?

Top MNKD Bull/Bear Pitches

 

Topdoginvesting1 (0)
Submitted June 30, 2014

Partnership or Buyout, no doubter..

0 Replies Reply Report this Post
 

usubanas (< 20)
Submitted March 28, 2014

predict FDA panel will vote negatively next week.

1 Replies Reply Report this Post

News & Commentary

Will FDA Labelling Be MannKind's Downfall?

While FDA approval may have come wrapped in a pretty box for shareholders, what is inside the box in terms of FDA warnings could be a huge problem for MannKind and Afrezza.

3 Longtime Losers About to See Green?

These 3 biotechs have lost tons of money every year so far in the 21st century. But could profits be on the horizon?

4 Stocks to Watch This Week

Let's look at the stocks that will be making news in the week ahead.

Is This MannKind's Greatest Risk?

MannKind won FDA approval for Afrezza but still faces risks. Is this one the biggest of all?

1 Key Question Remains after MannKind's Giant Leap

After FDA approval, now comes the hard part

Thirteen Analyst Stocks Under $10 With Huge Upside Potential

3 Things to Look for in MannKind's Partnership

Merck would be a perfect partner for MannKind; Novo Nordisk and Eli Lilly are likely out.

Biotech Stocks to Watch Today: AbbVie, Bind Therapeutics, MannKind, and Shire

Today's top stories in biotech and health care.

MannKind Poll Points to Bias That Stock Will Rise Above $15 into 2015

Should AstraZeneca Buy MannKind?

AstraZeneca (AZN) hopes to grow its diabetes revenue in the coming years and could benefit from adding MannKind's Afrezza to its product line up.

See More MNKD News...

Sector

Healthcare

Industry

Drugs

MannKind Corp (MNKD) Description

A biopharmaceutical company focused on the development and commercialization of therapeutic products for diseases such as diabetes and cancer. Website: http://www.mannkindcorp.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks